Download pdf
The Application of CAR-T Cell Therapy
- 1 School of Pinghe Bilingual School, Shanghai, China
* Author to whom correspondence should be addressed.
Abstract
Cancer is undoubtedly the number one killer in today's society. Traditional surgical treatment methods have their own limitations, especially in the treatment of end-stage or hematological tumors. Emerging immunotherapy is an unprecedented breakthrough technology in cancer treatment. For example, PD-1/PD-L1 and CAR-T immunotherapy. CAR-T has been proposed for many years, it is only in the last few years that it has been improved and applied in the clinic. Its effectiveness in the treatment of cancer in hematology is encouraging. For example, it has a great curative impact in the acute leukemia, in the field of non-Hodgkin lymphoma ,it is also recognized as one of the most prospective and developed tumor treatments. Clinical application of CAR-T has attracted extensive attention. This therapy is characterized by the ability to detect tumor-associated antigens preferentially detected by T cells, which has a significant anti-tumor effect. This article will focus on HCC, list the existing HCC CAR-T treatment targets and briefly describe associated clinical research.
Keywords
Hepatocellular, CAR-T Cell Therapy, Carcinoma
[1]. S.L. Maude, et al., Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England journal of medicine, 2014. 371(16): p. 1507-17.
[2]. M.L. Davila, et al., Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014. 6(224): p. 224ra25.
[3]. C.J. Turtle, et al., CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. The Journal of clinical investigation, 2016. 126(6): p. 2123-38.
[4]. D.M. Barrett, et al., Treatment of advanced leukemia in mice with mRNA engineered T cells. Human gene therapy, 2011. 22(12): p. 1575-86.
[5]. Z. Eshhar, et al. The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol. 1996;18(2):199-209.
[6]. K.M. Hege, et al. T-cell gene therapy. Curr Opin Biotechnol. 1996 Dec;7(6):629-34.
[7]. P. Braendstrup, et al. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020 Feb;22(2):57-69
[8]. C. Jin, et al. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Mol Med. 2016 Jul 1;8(7):702-11.
[9]. P. Muranski, et al. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol. 2006 Dec;3(12):668-81.
[10]. J. Guo, et al. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma[J]. Cancer Gene Therapy, 2021, 28(10): 1075-1087.
[11]. H. Liu, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T cell therapy for liver cancer[J]. Clinical Cancer Research, 2016:1078-0432.CCR-16-1203.
[12]. Y. Wang, et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial[J]. Oncoimmunology, 2018, 7(7): e1440169.
[13]. H. Dai, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial[J]. Oncoimmunology, 2020, 9(1): 1846926.
[14]. B. Sun, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells[J]. Cancer immunology research, 2019, 7(11): 1813-1823.
[15]. L. Zhang, et al. Immunotherapy for advanced hepatocellular carcinoma, where are we[J]. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2020, 1874(2): 188441.
[16]. S. C. Katz, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor–modified T-cell therapy for CEA+ liver metastases[J]. Clinical cancer research, 2015, 21(14): 3149-3159.
Cite this article
Yu,W. (2023). The Application of CAR-T Cell Therapy. Theoretical and Natural Science,4,7-12.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part II
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).